MDK’s management team was impressed by china sky one medical\'s state-of-the-art production facilities and its strict quality control system. MDK, which performed its own market research and financial forecasts, has the utmost confidence in the market prospects of the company\'s two new diagnostic kits. the distribution agreement has an initial trial period of three months. a more formal contract will be developed to define the annual sales guidelines.
The Ami diagnostic kit is used to diagnose early acute myocardial infarction and the human urinary albumin Elisa kit is used to diagnose early acute kidney disease. For the first nine months ended September 30, 2009, sales of the Ami diagnostic kit reached $7.5 million, accounting for approximately 7.5% of the company\'s total revenues. Sales of the human urinary albumin Elisa kit reached $1.6 million, accounting for approximately 1.6% of the company\'s total revenues, during the same period.
"We look forward to a successful collaboration with MDK on the sale of ourAMI diagnostic kit and our human urinary albumin Elisa kit, both of which have huge market potential," said Mr. Yan-qing liu, chairman and CEO of china sky one medical. "Our international sales team has already built a good market foundation in some Southeast Asian countries. We believe that MDK\'s mature sales network for medical devices will make this a mutually beneficial agreement."
"As part of our growth strategy, we will continue to expand our sales network in Southeast Asia, which is one of the most attractive overseas markets for china sky one medical due to its geographical and cultural proximity to china," Mr. liu added.